Incyte Corporation (INCY) has the Bigger Revenue Base, but Could Halozyme Therapeutics, Inc. (HALO) have the Better Economics?
On July 20, Halozyme Therapeutics, Inc.
Halozyme Therapeutics Inc. (HALO)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | D E Shaw D. E. Shaw | 2,006,479 | $157,047,112 | +8% | 0.07% |
| 2. | Arrowstreet Capital Peter Rathjens, Bruce Clarke And John Campbell | 1,704,623 | $133,420,842 | -12% | 0.06% |
| 3. | 66,016,000 | $96,739,001 | +164% | 0.01% | |
| 4. | 45,000,000 | $65,812,500 | 0.25% | ||
| 5. | AQR Capital Management Cliff Asness | 785,556 | $61,485,452 | -23% | 0.02% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $14.24 | 17,543 | $249,780.74 | 277,553 | 2020-03-19 | Filing | |
| $14.25 | 17,543 | $249,982.49 | 260,010 | 2020-03-19 | Filing | |
| $14.19 | 17,543 | $248,933.42 | 242,467 | 2020-03-19 | Filing | |
| $17.24 | 10,000 | $172,384.00 | 10,000 | 2015-08-20 | Filing | |
| $17.24 | 10,000 | $172,384.00 | 10,000 | 2015-08-20 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $107.55 | 4,508 | $484,826.38 | 767,780 | 2026-09-11 | Filing | |
| $107.15 | 15,492 | $1,660,029.77 | 772,288 | 2026-09-11 | Filing | |
| $107.58 | 5,412 | $582,228.37 | 767,780 | 2026-09-10 | Filing | |
| $107.01 | 14,588 | $1,561,091.06 | 773,192 | 2026-09-10 | Filing | |
| $108.67 | 100 | $10,867.00 | 767,780 | 2026-09-09 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 13,271,095 | $1,038,728,610 | 0.02% | |
| 2. | 5,351,312 | $418,847,190 | 0.01% | |
| 3. | 5,299,008 | $414,753,356 | 0.02% | |
| 4. | 5,179,434 | $405,379,779 | 0.01% | |
| 5. | 3,177,997 | $248,741,825 | 0.02% |
News See All
Q2 Earnings Blowouts: 37 Stocks That Beat Expectations
The ongoing earnings season has been a boon to listed companies' share prices in the second quarter of the year, helping offset macroeconomic uncertainties such as the US-Iran war, global trade, and questions...
8 Most Undervalued Growth Stocks to Buy for the Next 10 Years
Growth stocks aren’t supposed to be cheap. Investors willingly pay higher multiples for companies that are expected to grow earnings over the next few years.
Halozyme Therapeutics (HALO) Announces Global Collaboration and License Agreement With GSK
Halozyme Therapeutics, Inc. (NASDAQ:HALO) is one of the best healthcare stocks to buy for the long term. Halozyme Therapeutics, Inc.
Halozyme Therapeutics, Inc. (NASDAQ:HALO) Q1 2026 Earnings Call Transcript
Halozyme Therapeutics, Inc. (NASDAQ:HALO) Q1 2026 Earnings Call Transcript May 11, 2026Halozyme Therapeutics, Inc. beats earnings expectations. Reported EPS is $1.6, expectations were $1.54.
H.C. Wainwright Bullish on Halozyme Therapeutics, Inc. (HALO) Commercial Revenue Outlook
We recently compiled a list of the 10 Best Cancer Stocks to Buy for the Long Term. Halozyme Therapeutics, Inc. is one of the best cancer stocks to invest in. TheFly reported on April 29 that H.C.
10 Best Healthcare Stocks to Buy for the Long Term
In this article, we will look at the 10 Best Healthcare Stocks to Buy for the Long Term.
10 Best Cancer Stocks to Buy for the Long Term
In this article, we will be taking a look at the 10 Best Cancer Stocks to Buy for the Long Term.
Halozyme (HALO) Rated Buy on Strong Royalty Growth
Halozyme Therapeutics, Inc. (NASDAQ:HALO) ranks among the most profitable biotech stocks to buy now.
10 Most Profitable Biotech Stocks to Buy Now
In this article, we will take a look at the 10 Most Profitable Biotech Stocks to Buy Now.
Hedge Fund Resource Center